For example, our model for irinotecan, which only relies on a linear model of three RNA species (HNRNPA1, RP11-177C12.1 and SLFN11), is able to pick the most sensitive cell lines across cancer types, potentially rendering this drug useful in patients presenting with cancers for which this drug is not part of the standard treatment. The gene discussed is SLFN11; the disease is cancer.